LeMaitre Vascular Dividend and Recent Developments: Insights Ahead of Ex-Dividend Date Aug 21, 2025

Generated by AI AgentAinvest Dividend Digest
Sunday, Aug 17, 2025 7:04 pm ET1min read
Aime RobotAime Summary

- LeMaitre Vascular declared a $0.20/share dividend (ex-dividend: Aug 21, 2025), surpassing its 10-year average of $0.078/share.

- Director Lawrence Jasinski sold 976 shares ($90,553) amid insider trading concerns, while Q2 revenue rose 15% to $64.23M driven by international expansion.

- EMEA/Asia-Pacific regions saw 23%/12% sales growth, with analysts projecting 2025 revenue of $251M and EPS of $2.30.

- Cetera Investment Advisers bought 5,769 shares as LMAT was upgraded to 'Outperform,' highlighting its innovation-driven medical device leadership.

LeMaitre Vascular (LMAT) has announced a dividend of $0.200 per share, with an ex-dividend date set for Aug 21, 2025, and payment scheduled for Sep 4, 2025. This figure is significantly higher than the average of the last ten dividends, which stood at approximately $0.078 per share. The dividend type, translated from Chinese, is a cash dividend. The company last distributed dividends on May 29, 2025, maintaining the same per-share payout and dividend type.

Recently, has seen notable transactions and updates that could influence its market performance. Director Lawrence Jasinski sold 976 shares at $92.78 each on Aug 12, 2025, a transaction valued at $90,553. This move highlights insider trading activity, which might affect investor sentiment.

Over the past week, LeMaitre Vascular reported second-quarter earnings, revealing a 15% revenue growth to $64.230 million and a gross margin of 70%, driven by international expansion and a premium product mix. The EMEA region registered a 23% sales growth, with the APAC region following with a 12% increase, fueled by demand for vascular care and new product approvals. Analysts project 2025 revenue of $251 million and an EPS of $2.30, reflecting confidence in the company's scalable global model.

As of late, Cetera Investment Advisers acquired 5,769 shares, indicative of growing interest in LMAT’s stock. Furthermore, has been upgraded to 'Outperform' by analysts, reinforcing its position as a strong player in the medical device industry, known for its commitment to innovation and operational discipline.

In conclusion, LeMaitre Vascular is positioned as a compelling investment opportunity with its strategic expansions and promising financial health. Investors should note that Aug 21, 2025, is the last day to purchase LMAT shares to be eligible for the upcoming dividend. Any acquisitions made after this date will not qualify for this dividend distribution.

Comments



Add a public comment...
No comments

No comments yet